Find Funding Opportunities

Rescinded: Notice Encourage Eligible NIMH BRAIN Initiative Awardees Apply PA-16-288 Research Supplements Promote Diversity Health-Related Research Admin Supp)" Notice Number: NOT-MH-17-004 Key Dates Release Date: November 18, 2016 Rescinded December 6, 2016) Related Announcements NOT-MH-17-008 RFA-MH-15-200 RFA-MH-15-225 RFA-NS-15-003 RFA-NS-15-004 RFA-NS-15-005 RFA-NS-15-006 RFA-NS-15-008 RFA-EB-15-006 RFA-EY-16-001 RFA-MH-16-750 RFA-MH-16-775 RFA-MH-16-810 RFA-MH-16-815 RFA-NS-16-006 RFA-NS-16-007 RFA-NS-16-008 RFA-NS-16-009 RFA-NS-16-010 Issued National Institute Mental Health NIMH) National Institute Biomedical Imaging Bioengineering NIBIB) National Eye Institute NEI) National Institute Neurological Disorders Stroke NINDS) Purpose Notice to encourage eligible awardees the BRAIN Initiative community apply administrative supplements response PA-16-288, Research Supplements Promote Diversity Health-Related Research."  NIH a strong interest the diversity the NIH-funded workforce NOT-OD-15-053 details) encourages institutions diversify student populations enhancing participation individuals groups identified nationally underrepresented the biomedical, clinical, behavioral, social sciences NOT-OD-15-089 categories definitions). BRAIN Initiative 2025 report stated the BRAIN Initiative should a catalyst will drive outstanding young people enter area their most creative career stage."  NIH diversity supplement program offers opportunity existing BRAIN awardees request additional funds train mentor next generation researchers underrepresented groups will contribute advancing goals the BRAIN Initiative. Program Directors/Principal Investigators PDs/PIs) active BRAIN Initiative research program grants thus encouraged identify individuals groups nationally underrepresented support mentor under auspices the administrative supplement program promote diversity. Individuals the identified groups eligible throughout continuum high school the faculty level. activities proposed the supplement application must fall within scope the parent grant, both advance objectives the parent grant support research training professional development the supplement candidate. BRAIN Initiative PDs/PIs strongly encouraged incorporate research education activities will help prepare supplement candidate conduct rigorous research relevant the goals the BRAIN Initiative 2025 Report. Educational goals the NIH component the BRAIN Initiative BRAIN 2025: Scientific Vision) include acquisition quantitative skills, appropriate and integration newly developed tools, technologies methods developed under BRAIN Initiative, consideration the ethical implications neuroscience research. BRAIN 2025 Report notes individuals should obtain robust grounding quantitative reasoning, principles, techniques during training.  special focus training quantitative neuroscience, i.e. theory statistics biologists, exposing physicists, engineers statisticians experimental neuroscience. BRAIN 2025 Report strongly encourages scientists cross traditional areas expertise conduct interdisciplinary research, acknowledges need attract investigators faculty recruits neuroscience quantitative disciplines, e.g., statistics, computer science, physics, mathematics, engineering.   facilitate identification applications, first sentence the application's Project Summary should state following: parent grant a BRAIN Initiative award. PD/PI submitting administrative supplement enhance diversity response NOT-MH-17-004. Awarding Institutes have specific practices diversity research supplement requests augment requirements described PA-16-288.  Therefore, consultation the Program Official the qualifying BRAIN award the individual named under Inquiries below strongly encouraged.  Supplement applications be evaluated the BRAIN Initiative research training committee, committee Program staff the Institutes Centers participating the NIH BRAIN Initiative.  Applications be considered according the following schedule: Application Due Date                                    Funding Decision December 1, 2016 February 15, 2017          March 31, 2017 February 16, 2017 March 30, 2017              15, 2017 April 1, 2017 May 31, 2017                          July 15, 2017 tracking purposes, applicants encouraged inform Dr. Nancy Desmond via email Nancy.Desmond@nih.gov) a diversity supplement application submitted. Please include PD/PI name grant number this email. Inquiries Please direct inquiries to: Nancy L Desmond, Ph.D. National Institute Mental Health NIMH) Telephone: 301-443-3107 Email: Nancy.Desmond@nih.gov

Notice Intent Publish Funding Opportunity Announcement Zika Virus ZIKV) Complications R21) Notice Number: NOT-HD-16-033 Key Dates Release Date: November 17, 2016 Estimated Publication Date Announcement: December 2016-January 2017   First Estimated Application Due Date: February 16, 2017   Earliest Estimated Award Date: October-November 2017  Earliest Estimated Start Date: December 2017 Related Announcements NOT-HD-16-036 PAR-16-106 Issued National Institutes Health NIH) National Eye Institute NEI) National Institute Allergy Infectious Diseases NIAID) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Neurological Disorders Stroke NINDS) Purpose Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), other NIH Institutes Centers ICs) listed above, intends re-issue Funding Opportunity Announcement FOA) solicit applications research Zika Virus ZIKV) Complications. FOA replace PAR-16-106."Rapid Assessment Zika Virus ZIKV) Complications R21)" had issued provide expedited rapid) funding mechanism response the Zika virus public health emergency.  goal that initiative to respond quickly the public health emergency, reviewing applications rapidly, making timely awards support much needed projects.  a result this effort grants awarded support number highly meritorious projects were particularly urgent time-sensitive.  participating ICs intend continue commitment supporting Zika research, applications no longer accepted a rolling basis.  Instead re-issued FOA use standard application due dates the timeframes review, council award dates now align standard NIH practices. purpose this Funding Opportunity Announcement FOA) to solicit exploratory/developmental research projects Zika virus ZIKV) its complications.  ZIKV a single-stranded RNA virus the Flaviviridae family. is transmitted humans primarily through bites infected Aedes mosquitos, though both perinatal/in utero sexual transmission been reported.  Initially discovered 1947, has reported the Americas since 2014, a major outbreak Brazil starting 2015.  Disease seen about 20% infected people is usually self-limited.  However, possible association between ZIKV infection pregnant women severe microcephaly their babies been very concerning prompted World Health Organization declare potential complication public health emergency. Additionally virus been found blood, fueling growing concerns the risk transfusion-transmission with particular concern over severe outcomes at risk transfusion recipient populations such women are pregnant.  Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published December 2016-January 2017 an expected application due date February 2017. FOA utilize Exploratory/Developmental Research Grant R21) activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages investigators expertise insights appropriate areas science begin consider applying this new FOA. FOA solicit research projects determine whether ZIKV infection causes microcephaly other congenital abnormalities babies the potential rapid spread ZIKV the United States.  Additionally, research quantify risk the blood supply affected regions the potential clinical impact transfusion-transmission the Zika virus urgently needed inform strategies reduce prevent Zika transmission blood transfusion. Areas high priority include, are limited to, following: Demonstrate causative role infection pregnancy ZIKV the etiology fetal microcephaly, structural brain defects, other congenital malformations Basic research understand ZIKV infection pathogenesis transmission the fetus, immune responses immunological interactions other flaviviruses Population-based studies characterize epidemiology ZIKV infection the mother-infant dyad Clinical studies improve understanding the mechanisms risks maternal-to-child transmission ZIKV Strategies prevent transmission ZIKV the fetus after infection the mother Studies determine optimal screening and management ZIKV infection pregnant women in exposed fetuses Studies understand mechanisms which ZIKV affects developing nervous system other organ systems Development novel diagnostic, vaccine therapeutic strategies against Zika Studies Guillain-Barré Syndrome GBS), encephalitis encephalomyelitis associated ZIKV infection determine disease course outcomes, causality, disease mechanisms, effectiveness current treatments to develop novel treatments. Translational research the neurodevelopmental consequences infants exposure Zika Virus ZIKV) during pregnancy the early postnatal period better understanding potential ZIKV alter developing central nervous system social, cognitive, emotional, behavioral outcomes relevant mental health. Studies understand mechanisms which ZIKV affects developing nervous system infants, particularly brain regions associated social, cognitive, affective function more detailed list IC areas interest be found PAR-16-106. NOTE:  Clinical trials outside scope this FOA.   APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Nahida Chakhtoura MD, MsGH Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-435-6872 Email: nahida.chakhtoura@nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-1431 Email:  wongm@ninds.nih.gov Lillian Shum, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-0618 Email:  ShumL@mail.nih.gov Mark Challberg, PhD National Institute Allergy Infectious Diseases NIAID) Phone: 301-496-7453 Email: MCHALLBERG@niaid.nih.gov George McKie, DVM, PhD National Eye Institute NEI) Telephone: 301-435-8152 Email: mckiegeo@nei.nih.gov Šeila Selimovic, Ph.D. National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-451-4577 Email:  Seila.Selimovic@nih.gov 

Notice Informational Webinar the NIH Blueprint Diversity Specialized Predoctoral Postdoctoral Advancement Neuroscience D-SPAN) Award F99/K00) Notice Number: NOT-NS-17-008 Key Dates Release Date: November 8, 2016   Related Announcements RFA-NS-17-009 Issued National Institute Neurological Disorders Stroke NINDS)  Purpose Notice to inform potential applicants mentors to the RFA-NS-17-009 quot;NIH Blueprint Diversity Specialized Predoctoral Postdoctoral Advancement Neuroscience D-SPAN) Award F99/K00)" an upcoming informational webinar preparing applications this award. webinar optional not required submission RFA-NS-17-009. purpose the NIH Blueprint Diversity Specialized Predoctoral Postdoctoral Advancement Neuroscience D-SPAN) Award to support defined pathway across career stages outstanding graduate students are diverse backgrounds underrepresented neuroscience research. two-phase award facilitate completion the doctoral dissertation transition talented graduate students strong neuroscience research postdoctoral positions, will provide career development opportunities relevant their long-term career goal becoming independent neuroscience researchers. the F99/K00 award, individuals receive to 6 years combined support both phases, includes to 2 years the F99 fellowship phase up 4 years the K00 career development phase. Webinar Information Informational Webinar the NIH Blueprint Diversity Specialized Predoctoral Postdoctoral Advancement Neuroscience D-SPAN) Award F99/K00) January 18, 2017 1:00 - 3:00 p.m. Eastern Time webinar take through process putting together application the NIH Blueprint Diversity Specialized Predoctoral Postdoctoral Advancement Neuroscience D-SPAN) Award. webinar go through part the application, including eligibility, specific aims research strategy, sponsor co-sponsor information, letters reference support, the certification letter. second half the webinar be question answer session attendees. register the webinar, please follow following link: https://nih.webex.com/nih/onstage/g.php?MTID=eed329c2becd5b4115d7ab479c…. registration link available the bottom the page. Inquiries Please direct inquiries to: Michelle Jones-London, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: jonesmiche@ninds.nih.gov

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System UG3/UH3) Notice Number: NOT-NS-17-005 Key Dates Release Date: October 27, 2016 Estimated Publication Date Announcement: February 14, 2017     First Estimated Application Due Date: August 11, 2017  Earliest Estimated Award Date: February 2018   Earliest Estimated Start Date: March 2018  Related Announcements None     Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Aging NIA) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) Purpose NIH announces intention reissue PAR-14-293 investigators seeking support the Blueprint Neurotherapeutics BPN) Network.  Applicants be encouraged utilize customized set contract resources, consultants the BPN Network help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. This FOA utilize UG3/UH3 activity code. Details the planned FOA provided below. FOA expected be published February 2017 an expected application due date August 2017.   Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics BPN) Network, collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. planned reissue Funding Opportunity Announcement FOA) encourage applications investigators seeking funding through UG3/UH3 phased cooperative agreement mechanism help advance drug discovery development projects the clinic.  Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. projects enter BPN begin a preparatory phase UG3) up one year, can used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please see    http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) Telephone:301-496-1779 Email: cywincl@ninds.nih.gov

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44) Notice Number: NOT-NS-17-006 Key Dates Release Date: October 27, 2016 Estimated Publication Date Announcement: February 14, 2017     First Estimated Application Due Date: August 11, 2017  Earliest Estimated Award Date: February 2018   Earliest Estimated Start Date: March 2018  Related Announcements None     Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Aging NIA) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) Purpose NIH announces intention reissue PAR-14-292 SBIR-eligible small businesses seeking support the Blueprint Neurotherapeutics Network BPN). Applicants encouraged utilize customized set contract resources, consultants the Blueprint Neurotherapeutics Network BPN) help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA utilize U44 activity code.  Details the planned FOA provided below. FOA expected be published February 2017 an expected application due date August 2017. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics Network BPN), collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. reissued Funding Opportunity Announcement FOA) encourage applications SBIR-eligible small businesses seeking funding through Fast-Track phased U44 cooperative agreement mechanism help advance drug discovery development projects the clinic.  Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. Discovery projects begin a U44 Phase award up two years. first 6-12 months be used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) Telephone:301-496-1779 Email: cywincl@ninds.nih.gov

Notice Interest High Priority Research Bioethical, Legal, Societal Implications Biomedical Research Notice Number: NOT-LM-17-001 Key Dates Release Date: October 25, 2016   Related Announcements NOT-HL-16-471 Issued National Cancer Institute NCI) National Eye Institute NEI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Minority Health Health Disparities NIMHD) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Library Medicine NLM) National Center Complementary Integrative Health NCCIH) Purpose listed NIH ICs issuing Notice highlight interest empirical conceptual research addressing high priority bioethical, legal, societal challenges impacting biomedical research.  Areas high priority research include, are limited to, bioethical, legal societal implications the following: New emerging technology development use, such as: gene drive; precision gene editing; artificial intelligence; brain implants modulation; human-animal chimeras Clinical non-clinical data sharing; big data data science analytics; integration data research, including clinical, research, environment, social media, patient provided, other Precision personalized medicine; personal, institutional, research privacy security Learning Healthcare System; interface clinical research clinical care; pragmatic trials Crowdsourcing; participant driven, directed, sponsored clinical research; Citizen Science DIY biomedical research Special vulnerable population research, including pediatric, end-of-life-care, emergency, disaster, pandemic research; issues capacity impaired individuals populations Individual community health, treatment, and/or research disparities; international research Current emerging regulatory environments Informed consent issues Innovative study design, conduct, management, oversight Possible funding opportunities can used pursue research activities include: PA-16-160 NIH Research Project Grant Parent R01) PA-16-161 NIH Exploratory/Development Research Grant Program Parent R21) PA-16-162 NIH Small Research Grant Program Parent R03) PA-16-200 Academic Research Enhancement Award Parent R15) Investigators interested developing applications bioethics, legal, societal implications research strongly encouraged discuss ideas specific IC contacts listed below prior submission ICs varying levels interest high priority areas.  Potential applicants should also discuss specific IC contacts most appropriate mechanism their proposed project all ICs not utilize parent FOAs listed above hyperlinks each FOA above).  Applicants should clearly state the cover letter, Project Abstract, Specific Aims sections the grant application they responding this particular NOT.  cover letter should also indicate IC contact consulted prior submission.  Applications responding this should submitted the regular application due dates will reviewed NIH standing study sections. Inquiries Please direct inquiries to: Charlisse Caga-Anan, JD MA National Cancer Institute NCI) Telephone: 240 276-6738 Email: charlisse.caga-anan@nih.gov Sangeeta Bhargava, PhD National Eye Institute NEI) Telephone: 301-451-2020 Email: Sangeeta.Bhargava@nih.gov Jean McEwen, JD PhD National Human Genome Research Institute NHGRI) Telephone: 301 402-4997 Email: jm522n@nih.gov Chyren Hunter, PhD National Institute Aging NIA) Telephone: 301 496-9322 Email: hunterc@mail.nih.gov Liza Dawson, PhD National Institute Allergy Infectious Diseases NIAID) Telephone: 240 627-3210 Email: dawsonl@niaid.nih.gov Laura Moen, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301 451-6515 Email: moenl@mail.nih.gov Troy Zarcone, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-1285 Email: troy.zarcone@nih.gov Nancy Jones, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-8945 Email: nancy.jones@nih.gov Steven Krosnick, MD National Institute Biomedical Imaging Bioengineering NIBIB) Telephone:  301-594-3009 Email: krosnics@mail.nih.gov Lana Shekim, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301 496-5061 Email: shekiml@nidcd.nih.gov Lynn Mertens King, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301 594-5006 Email: lynn.king@nih.gov Ruben Baler, PhD National Institute Drug Abuse NIDA) Telephone: 301 480-2733 Email:  balerr@mail.nih.gov Symma Finn, PhD National Institute Environmental Health Sciences NIEHS) Telephone: 919 698-5574 Email: finns@niehs.nih.gov Matthew V. Rudorfer, M.D. National Institute Mental Health NIMH) Telephone: 301) 443-1111 Email: mrudorfe@mail.nih.gov Adam L Hartman, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301 496-9135 Email: adam.hartman@nih.gov Lynn Adams, PhD National Institute Nursing Research NINR) Telephone: 301 594-8911 Email: adamsls@mail.nih.gov Valerie Florance, PhD National Library Medicine NLM) Telephone: 301 496-4621 Email: florancev@mail.nlm.nih.gov Wendy Weber, ND PhD MPH National Center Complementary Integrative Health NCCIH) Telephone: 301-402-1272 Email: weberwj@mail.nih.gov  

Notice Informational Webinars NINDS Diversity Career Development Awards K series) Notice Number: NOT-NS-17-007 Key Dates Release Date: October 21, 2016 Related Announcements PAR-16-219 PAR-16-220 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants mentors to NINDS Mentored Career Development Awards Promote Diversity Neuroscience K22 PAR-16-220 K01 PAR-16-219) upcoming webinars on preparing applications these mechanisms. webinars optional not required submission PAR-16-220 PAR-16-219. be notified upcoming webinars other diversity-related opportunities, please subscribe the NINDS Diversity News Use listserv https://list.nih.gov/cgi-bin/wa.exe?A0=NINDSDIVERSITYNEWSTOUSE. Webinar Information You Need Know the NINDS Diversity Career Development K22 Award: Tips Preparing Application December 13, 2016 3:00-4:00 p.m. Eastern Time Learn the NINDS K22 Diversity Career Development Award successful applicants a former chair the study section reviews mechanism. webinar take through process putting together application the Diversity Advanced Postdoctoral Career Transition Award K22) the from writing application anticipating responding reviewer's comments. Hear two K22 awardees how crafted applications, learn a reviewer common mistakes helpful tips. webinar intended potential applicants mentors NINDS diversity K22 grants. register the webinar, please follow following link: https://nih.webex.com/nih/onstage/g.php?MTID=ed1bff7e922ffe0174438f82dc…. registration link available the bottom the page. You Need Know the NINDS Diversity Faculty Development K01 Award: Tips Preparing Application Anticipated March 2017, date time be determined Inquiries Please direct inquiries to: Michelle Jones-London, PhD National Institute Neurological Disorders Stroke NINDS)  Telephone: 301-496-4188 Email: NINDSDiversityTraining@ninds.nih.gov

Notice Intent Publish Funding Opportunity Announcement Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ME/CFS) Collaborative Research Centers CRCs) U54) Notice Number: NOT-NS-17-003 Key Dates Release Date: October 21, 2016 Estimated Publication Date Announcement: December 2016  First Estimated Application Due Date: April 2017 Earliest Estimated Award Date: September 2017  Earliest Estimated Start Date: September 2017   Related Announcements RFA-NS-17-021 NOT-NS-17-004 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), along other NIH Institutes Centers ICs), intends promote new initiative publishing Funding Opportunity Announcement FOA) solicit applications research myalgic encephalomyelitis/chronic fatigue syndrome ME/CFS).  FOA invite applications ME/CFS Collaborative Research Centers CRCs). overarching goal this initiative be establish network Centers will work independently collaboratively define causes and discover improved treatments ME/CFS.  purpose the ME/CFS CRC research program to facilitate research ME/CFS through support 1) collaborative basic clinical research ME/CFS, including longitudinal studies individuals ME/CFS within ME/CFS CRC across CRCs within network; 2) foster early stage basic clinical investigators ME/CFS research; 3) provide access information related ME/CFS basic clinical researchers, academic practicing physicians, healthcare professionals, individuals ME/CFS, the lay public. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA the ME/CFS CRCs utilize U54 activity code cooperative agreements, will allow substantial NIH involvement the awardees. FOA expected be published December 2016 an expected application due date April 2017. NIH anticipates holding pre-application web-based teleconference which interested prospective applicants invited. Information this pre-application web-based teleconference call be available the FOA. Details the planned ME/CFS CRC FOA provided below. Clinical basic science data management efficient data collection well data mining data sharing be addressed through separate FOA cooperative agreements be issued the Data Management Coordinating Center DMCC).  Details regarding Data Management Coordinating Center FOA be found NOT-NS-17-004. Research Initiative Details Notice encourages investigators expertise insights this area ME/CFS begin consider applying this new FOA. intended FOA solicit applications propose research ME/CFS. initiative support multidisciplinary, collaborative research teams investigate underlying basic mechanisms cause ME/CFS to work toward development new treatments ME/CFS.  is encouraged, not required, investigators partner the Clinical Translational Science Award CTSA) investigators their institution(s).  Center also expected collaborate other funded Centers, coordinate research data collection management the Data Management Coordinating Center. Applicants encouraged, not required use multiple program director/principal investigator PD/PI) mechanism facilitate collaborations between clinicians basic scientists.  Multidisciplinary teams diverse areas expertise be represented may located different institutions.  Foreign components allowed, applications foreign institutions not allowed under FOA. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Vicky Whittemore, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: vicky.whittemore@nih.gov

Notice Intent Publish Funding Opportunity Announcement Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ME/CFS) Data Management Coordinating Center DMCC) U01) Notice Number: NOT-NS-17-004 Key Dates Release Date: October 21, 2016 Estimated Publication Date Announcement: December 2016  First Estimated Application Due Date: April 2017 Earliest Estimated Award Date: September 2017  Earliest Estimated Start Date: September 2017    Related Announcements RFA-NS-17-022 NOT-NS-17-003 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), along other NIH Institutes Centers ICs), intends promote new initiative publishing Funding Opportunity Announcement FOA) solicit applications a Data Management Coordinating Center DMCC) facilitate coordinate research the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Collaborative Research Centers ME/CFS CRC). overarching goal this initiative be establish data management coordinating center will support work a network ME/CFS CRCs will work independently collaboratively define causes and discover improved treatments ME/CFS will coordinate activities through DMCC. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published December 2016 an expected application due date April 2017. NIH anticipates holding pre-application web-based teleconference which interested prospective applicants invited. Information this pre-application web-based teleconference call be available the FOA. FOA utilize U01 activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages investigators expertise insights this area data management coordination begin consider applying this new FOA. Clinical basic data management efficient data collection well data mining data sharing be addressed through FOA the Data Management Coordinating Center DMCC) component support ME/CFS CRCs.  DMCC support collaborative research teams the ME/CFS CRCs manage coordinate research data collection the Data Management Coordinating Center. Applicants encouraged, not required use multiple program director/principal investigator PD/PI) mechanism facilitate collaborations.  Multidisciplinary teams diverse areas expertise be represented.  Foreign components allowed, applications foreign institutions not accepted. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Vicky Whittemore, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: vicky.whittemore@nih.gov

Notice Clarification Regarding Country Eligibility PAR-17-001 Emerging Global Leader Award K43)" Notice Number: NOT-TW-17-002 Key Dates Release Date: October 21, 2016 Related Announcements NOT-TW-17-008 PAR-17-001 NOT-TW-12-011 Issued Fogarty International Center FIC) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Research Women’s Health ORWH) Purpose purpose this Notice to clarify eligibility PAR-17-001 Emerging Global Leader Award K43)". Specifically, Notice clarifies country eligibility requirements institutions individuals reflect Country Eligibility Fogarty International Training Grants. Part 2. Section III. Eligibility Information 1. Eligible Applicants Foreign Institutions Currently reads Only non-domestic non-U.S.) Entities Foreign Institutions) Low- Middle-Income Countries eligible apply. LMICs defined the World Bank classification system according Gross National Income GNI) per capita low-income,” lower-middle-income,” upper-middle-income” http://data.worldbank.org/about/country-classifications/country-and-len…). Non-domestic non-U.S.) components U.S. Organizations not eligible apply. Foreign components, defined the NIH Grants Policy Statement, allowed. Modified read sentence added italicized below) Only non-domestic non-U.S.) Entities Foreign Institutions) Low- Middle-Income Countries eligible apply. LMICs defined the World Bank classification system according Gross National Income GNI) per capita low-income,” lower-middle-income,” upper-middle-income” http://data.worldbank.org/about/country-classifications/country-and-len…). Country Eligibility Fogarty International Training Grants additional information.  Non-domestic non-U.S.) components U.S. Organizations not eligible apply. Foreign components, defined the NIH Grants Policy Statement, allowed. Part 2. Section III. Eligibility Information 1. Eligible Applicants Eligible Individuals Program Director/Principal Investigator) Currently reads Any candidate the skills, knowledge, resources necessary carry the proposed research the Program Director/Principal Investigator PD/PI) invited work his/her primary mentors U.S.-based one LMIC-based) organization develop application support. Individuals underrepresented racial ethnic groups well individuals disabilities always encouraged apply NIH support. Multiple PDs/PIs not allowed. applicant must an LMIC citizen and, the time award, not a citizen a non-citizen national the United States have lawfully admitted permanent residence i.e., possess currently valid Permanent Resident Card USCIS Form I-551, other legal verification such status). Modified read sentence added italicized below) Any candidate the skills, knowledge, resources necessary carry the proposed research the Program Director/Principal Investigator PD/PI) invited work his/her primary mentors U.S.-based one LMIC-based) organization develop application support. Individuals underrepresented racial ethnic groups well individuals disabilities always encouraged apply NIH support. Multiple PDs/PIs not allowed. applicant must an LMIC citizen and, the time award, not a citizen a non-citizen national the United States have lawfully admitted permanent residence i.e., possess currently valid Permanent Resident Card USCIS Form I-551, other legal verification such status). Country Eligibility Fogarty International Training Grants additional information.  other aspects this FOA remain same. Inquiries Please direct inquiries to: Christine Jessup, Ph.D. Fogarty International Center FIC) Telephone: 301-496-1653 Email: christine.jessup@nih.gov